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Abstract: Background. Cellular immune suppression is
observed in head and neck squamous cell cancer (HNSCC)
and contributes to poor prognosis. Restoration of immune
homeostasis may require primary cell-derived cytokines at
physiologic doses. An immunotherapy regimen containing a
biologic, with multiple-active cytokine components, and admin-
istered with cytoxan, zinc, and indomethacin was developed to
modulate cellular immunity.
Methods. Study methods were designed to determine the
safety and efﬁcacy of a 21-day neoadjuvant immunotherapy regi-
men in a phase 2 trial that enrolled 27 therapy-naı¨ve patients with
stage II to IVa HNSCC. Methods included safety, clinical and
radiologic tumor response, disease-free survival (DFS), overall
survival (OS), and tumor lymphocytic inﬁltrate (LI) data collection.
Results. Acute toxicity was minimal. Patients completed
neoadjuvant treatment without surgical delay. By independent
radiographic review, 83% had stable disease during treatment.
OS was 92%, 73%, and 69% at 12, 24, and 36 months,
respectively. Histologic analysis suggested correlation
between survival and tumor LI.
Conclusion. Immunotherapy regimen was tolerated. Sur-
vival results are encouraging. VC 2011 Wiley Periodicals, Inc.
Head Neck 33: 1666–1674, 2011
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Head and neck squamous cell carcinoma (HNSCC) is
common, representing about 6% of all cancers, with
an estimated 644,000 new cases and 352,000 cancer
deaths worldwide each year.1 In the United States, it
was estimated that head and neck cancers in 2008
would have accounted for 3.3% (47,560) of all new
cancer diagnoses and 2% (11,260) of all cancer
deaths.2 Despite more aggressive treatments, the
overall 5-year relative survival rate for HNSCC has
not changed substantially, and remains at 50% to
59%.3,4 New treatments with limited toxicity are
needed that can enhance or replace current regimens,
with the goal of improving the survival rate, preserv-
ing organ function, and enhancing the quality of life
of patients with HNSCC.
Many patients with HNSCC are found to have
defects in both innate and adaptive immunity that
include dendritic cell and T cell dysfunction.5–7 In
patients with HNSCC, immunologic changes in lymph
nodes have also been reported to be related to
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survival,8 whereas systemic T-cell counts are often
low in HNSCC6,9 and are negatively associated with
survival.10 Current treatments, including surgery,
radiation therapy, and chemotherapy, further exacer-
bate cellular immune deﬁciencies. Attempts at modu-
lating the immune system to treat cancer have been
attempted for almost a century with only limited suc-
cess. However, with the recent growth in understand-
ing of tumor biology and immune regulatory function,
new approaches have been developed over the last
decade that seem to have increased potential for suc-
cess. Early studies with immunomodulatory cyto-
kines, such as interleukin 2 (IL-2), have had mixed
results and have relied on traditional high-dose drug
testing paradigms, which may not be the best applica-
tion of these biological agents, given their adverse
effects and the fact that biological systems often func-
tion within physiologic ranges where more is not nec-
essarily better. These observations identify HNSCC
as a good candidate for immunotherapy.
In an attempt to restore immune homeostasis and
potentially enhance an immunologically-mediated
antitumor response, we conducted a multicenter
phase 2 clinical trial of a novel neoadjuvant immuno-
logic approach based on subcutaneous injections of
physiologic quantities of multiple cytokines combined
with low-dose immunomodulatory cyclophosphamide,
indomethacin, and zinc.
The major component of this immunotherapy regi-
men (IRX-2, IRX Therapeutics, New York, NY) is a
primary cell-derived biologic, containing physiologic
quantities of T helper type 1 (TH1) cytokines and
monokines, that has been shown in preclinical studies
to enhance cell-mediated immune response.11 The pri-
mary active components are interleukin (IL)-2, IL-1b,
gamma interferon (c-IFN), and tumor necrosis factor
alpha (TNF-a).12 These components are produced in
vitro from lymphocytes and monocytes by stimulation
with phytohemagglutinin. Preclinical studies in immu-
nodeﬁcient animal models have found an increase in
both CD4þ and CD8þ T cells after treatment with
such human, primary cell-derived cytokines.11 To
achieve better cytokine efﬁcacy in patients with multi-
ple defects in cellular immunity, the design of the
immunotherapy regimen includes additional drug
strategies to enhance immune responsiveness. Low-
dose cyclophosphamide is used because it has been
shown to enhance cell-mediated immune response by
depleting and inhibiting immunosuppressive regula-
tory T cells.13 The use of non-steroidal anti-inﬂamma-
tory drugs such as indomethacin has also been
demonstrated to activate immune responses and
increase tumor inﬁltration in patients with cancer by
reducing the immune suppressing effect of prostaglan-
dins.14,15 Zinc supplementation is added because the
trace metal zinc plays an important role in the devel-
opment and function of cellular immunity.16 Further-
more, zinc deﬁciency, observed in 50% of patients with
HNSCC, is associated with increased tumor size and
higher overall cancer stage, and negatively affects
disease-free interval.17 Therefore, an immunotherapy
regimen was designed to include zinc, indomethacin,
and low-dose cyclophosphamide in addition to the pri-
mary cell-derived active cytokines. This regimen was
named IRX-2 by the biotechnology company that
developed it.
The rationale for the immunotherapy regimen
and trial design was supported by observations that
tumor-draining neck lymph nodes often contain tu-
mor cells in a microenvironment that is immunosup-
pressive. Before surgery, the multiple active cytokines
are injected subcutaneously into the base of the neck
and absorbed into the lymphatics, activating regional
lymph node immune cells, theoretically, and allowing
priming of an antitumor response. It is hypothesized
that the elicited antitumor immune response could
destroy any remaining microscopic or disseminated
tumor cells and contribute to long-term antitumor
immunity postsurgical resection and subsequently
enhance long-term survival.
The same immunotherapy regimen administered
in this report was previously given to 13 patients
with advanced HNSCC whose surgery and/or radia-
tion therapy was unsuccesful in a phase 1 clinical
safety study.18 The most frequent adverse events
(AEs) were observed in the blood and lymphatic
system and the gastrointestinal system, with lympho-
penia in 4 patients; and anemia, abdominal pain, and
dysphagia in 3 patients each. Anorexia, headache,
and dyspnea were each reported in 3 patients. There
were 3 patients (23%) who discontinued participation
from the study prematurely due to an AE. Of these, 2
patients (16%) died of causes not related to the immu-
notherapy regimen. One patient (8%) had mental sta-
tus changes. Two more patients died after the study
period due to tumor progression. None of the deaths
or discontinuations was considered related to the
immunotherapy regimen. AEs attributed as probably
drug-related included injection-site reaction in 2
patients and injection-site pain in 1 patient. Possibly
related AEs were lymphopenia and pain in 2 patients
each, followed by leukocytosis, neutrophilia,
thrombocythemia, tinnitus, malaise, nasopharyngitis,
and hypotension, each observed in 1 patient. For in-
domethacin, probably related AEs were abdominal
pain in 2 patients, and nausea and anorexia, each
observed in 1 patient. Dizziness in 1 patient was con-
sidered possibly related to cyclophosphamide, and
constipation in 1 patient was reported as possibly
related to zinc gluconate. The most frequent grade 3
(severe) AEs were dysphagia in 2 patients (a third
patient had grade 1 dysphagia) and dehydration in 2
patients. There were no grade 4 (life-threatening)
AEs. Of the 2 patients with grade 5 AEs (death), 1
died of multi-organ failure and the other died of sub-
arachnoid hemorrhage. Neither of these grade 5 AEs
(death) was considered related to the study drugs.
There were 7 patients with a total of 13 serious
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adverse events (SAEs). Only 1 AE, hypotension, was
considered by the investigator as possibly related to
the cytokine-containing biologic, whereas an acute
renal failure was deﬁned as unlikely to be related to
indomethacin. Antitumor responses were noted by ra-
diographic assessment. In the 8 patients who had
antitumor data at day 21, 1 patient had complete
response, 5 patients had stable disease, and 2
patients had progressive disease.
The primary goal of this phase 2 study was to fur-
ther evaluate the safety and efﬁcacy of this immuno-
therapy regimen in the neoadjuvant setting in
previously untreated patients with advanced HNSCC
undergoing surgery with curative intent.
PATIENTS AND METHODS
Patient Population. Previously untreated patients
were consecutively screened at 16 academic research
centers and invited to participate in the study. Eligible
patients had stage II to IVa, histologically proven,
squamous cell carcinoma of the oral cavity, orophar-
ynx, hypopharynx, or larynx, were aged from 18 to 80
years (n ¼ 27), and had a Karnofsky performance sta-
tus 70%. Patients were excluded if they were cur-
rently under immunosuppressive therapy, used any
investigational agent, had undergone surgery, radio-
therapy, or chemotherapy within the previous 30 days,
or had known allergies or sensitivities to study drugs.
Institutional review boards at each of the 16 partici-
pating centers individually approved the study. Twelve
of the 16 centers enrolled patients. All patients gave
informed consent, and the experimental protocol was
approved by the individual Institutional Review Board
for Human Experimentation at each participating
institution.
The Immunotherapy Regimen and Treatment Sched-
ule. The immunotherapy regimen is a 21-day neoad-
juvant immune restorative treatment regimen to be
followed by surgery with curative intent. The cyto-
kine biologic, also referred to as IRX-2, contains phys-
iologic quantities of cytokines, which are measured by
quantitative enzyme-linked immunosorbent assay
and serve as product release criteria.21 In addition to
the cytokines that deﬁne product release, IRX-2 also
contains IL-6, IL-8, granulocyte colony-stimulating
factor, and granulocyte macrophage colony-stimulat-
ing factor. Drug product dosing is based on 4 primary
cytokine components that are listed in Table 1. The
cytokine biologic is produced from healthy blood
donors’ leukocytes obtained from United States Food
& Drug Administration (FDA) licensed blood centers.
Puriﬁed mononuclear cells were prepared and stimu-
lated with phytohemagglutinin to induce cytokine
production. The good manufacturing process ensures
consistency, safety from bloodborne pathogens, and
adherence to FDA guidelines for good manufacturing
process biologics production under an approved
United States Investigational New Drug application.
Each biologic lot was tested for adherence to FDA-
approved speciﬁcations, for content of IL-2, IL-1b, c-
IFN, TNF-a, for protein, for sterility, and for the ab-
sence of various viruses and endotoxin.
The subcutaneous immunotherapy injections were
administered over 10 days (Monday through Friday
over a 2-week period) as 2 bilateral injections of 115
U each in the mastoid region of the left and right
necks in close proximity to the regional nodal basins.
The regimen also included a 1-time infusion of a non-
cytotoxic dose of cyclophosphamide (300 mg/m2) on
day 1, and daily oral indomethacin (25 mg; 3 times
daily) and zinc gluconate (24 mg; 1 daily) for 21 days.
Although not considered part of the regimen, daily
omeprazole (20 mg; 1 daily) for 21 days was recom-
mended as supportive care to decrease potential
gastric symptoms related to the indomethacin. Post-
treatment patient and tumor assessments were car-
ried out on day 21. Patients were assessed for AEs
and toxicity during treatment and for 30 days after
surgery. The protocol recommended that investigators
give postoperative radiation therapy, especially in
patients with suspected microscopic residual disease.
In addition, postoperative chemotherapy concurrent
with radiation therapy was advised for candidates
where appropriate and in accordance with recommen-
dations of recent cooperative study ﬁndings. Study
design included periodic patient follow-up for 5 years
after surgery.
Safety and Tumor Assessment. The primary study
objective was to demonstrate the safety of this immu-
notherapy regimen based on AEs, changes in clinical
laboratory measures (hematology, chemistry, and uri-
nalysis were determined at baseline, day 1, day 8,
day 15, day 21; and 1, 3, 6, 9, 12, 18, 24, 30, 36, 48,
and 60 months postsurgery), vital signs, and physical
examinations. Stools for guaiac were collected at
baseline and as clinically indicated through day 21.
SAEs were collected throughout the treatment and 30
days postoperatively. AEs were graded according to
the National Cancer Institute Common Terminology
Criteria for Adverse Events (version 3.0). All serious
SAEs were followed to resolution. A sample size of 25
patients was determined based on the assumption
that, for any given category of safety risk, if no event
Table 1. Phase 2 lots cytokine unit dosing.
Lot no.
IL-1b
(ng/mL)
IL-2
(ng/mL)
c-IFN
(ng/mL)
TNF-a
(ng/mL)
2050426 0.6 5.8 1.5 1.8
2007001 0.7 6.4 2.6 2.3
2007002 0.7 5.9 2.1 1.6
Abbreviations: IL-1b, interleukin 1 beta; IL-2, interleukin 2; c-IFN, gamma interferon;
TNF-a, tumor necrosis factor alpha.
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of that type occurs, one can rule out that the true
rate of occurrence of that type of risk is at least 12%.
If the true frequency of a given adverse event is 5%,
a study of 25 patients would provide 87% power to
exclude a likelihood of that event of greater than
25%.
Secondary objectives were clinical, pathologic, and
radiographic tumor response; and patient disease-free
survival (DFS) and overall survival (OS). Tumor
response data were prospectively evaluated using
modiﬁed Response Evaluation Criteria in Solid
Tumors (RECIST) based on central independent
radiologic evaluation at baseline and day 21 (after
completion of immunotherapy but before surgery).
Data collected included a description of the change in
the sum of the longest diameters of all target lesions.
A tumor response was categorized as ‘‘progression’’ if
there was an increase of single longest diameter of
>20%, and as a ‘‘partial response’’ if there was a
decrease in the single longest diameter of >30%. Pre-
treatment and posttreatment CT or MRI scans were
compared, with no clinical information provided, by
centralized independent reviewers (Perceptive Infor-
matics, Waltham, MA). The recording of baseline data
was done without seeing the day-21 scan.
Tumor pathology was evaluated from tissue
specimens obtained at tumor resection. Formalin-
ﬁxed, parafﬁn-embedded blocks, or unstained slides
from the primary tumor were submitted to an
independent pathology laboratory (PhenoPath Labo-
ratories, Seattle, WA) for hematoxylin and eosin
staining, and evaluation of lymphocyte inﬁltration.
It was estimated that up to 70% of patients would
demonstrate substantial biologic effect as deﬁned by
a 20% or greater increase in tumor lymphocyte inﬁl-
tration. If at least 20 patients were included in the
sample size, the 95% 2-sided conﬁdence intervals for
20% response would range from 0.03 to 0.37.
Changes in laboratory values and clinical symptoms
related to treatment were also recorded during treat-
ment and on day 21 posttreatment.
Survival Assessments. The intent-to-treat popula-
tion included all patients who entered the study and
received any amount of any component of the immu-
notherapy regimen. Analyses and evaluations of DFS
and OS outcomes were determined.
Measure of Lymphocytic Inﬁltrate. An independent
review of tumor-inﬁltrating lymphocytes was per-
formed on representative tumor sections from sam-
ples obtained at surgery for analysis using a 100-mm
visual analog scale (VAS) as an assessment of lym-
phocytic inﬁltrate (LI). Tumor specimens were evalu-
able in 24 of the 27 patients; 1 patient refused
surgery, there was not enough tumor to analyze in 1
patient, and in 1 patient no tumor was visible in the
resected specimen. A blinded VAS reading of hema-
toxylin-eosin-stained sections was performed for LI,
with 100 mm signifying LI encompassing the entire
primary tumor section or maximum LI, and 0 mm
signifying no LI in the tumor specimen. The patients
were then grouped for analysis into high-LI and low-
LI cohorts based on a mean VAS cutpoint of 23 mm.
Quality Control. A surgical quality control commit-
tee (authors G.T.W., J.S.M., and principal investigator
W.K.) was used to prospectively assure proper tumor
staging, patient eligibility, adherence to protocol sur-
gical guidelines, and to review all operative and pa-
thology reports. As described above, independent
central laboratories were used to evaluate imaging
quality, peripheral blood, serum, and histopathology
results.
RESULTS
Patient Characteristics. Mean patient age was 57
years (range, 36–79 years). Twenty patients (74%)
were men. Fifteen patients had oral cavity cancer, 8
patients had oropharyngeal cancer, 1 patient had
hypopharyngeal cancer, and 3 patients had laryngeal
cancer. Most patients (89%) had Karnofsky perform-
ance status >80. Three patients had stage II disease,
8 patients had stage III, and 16 patients had stage
IVa (60%). Nodal class was N0 in 5 patients, N1 in 8
patients, and N2 in 14 patients; no patient had N3
disease.
Toxicity. The 21-day neoadjuvant immunotherapy
regimen was well tolerated with minimal toxicity.
Compliance was excellent; all patients completed the
regimen. Of the 26 patients completing surgery, 19
received surgery and postsurgical radiation therapy
and 10 of the 19 patients also received chemotherapy.
One patient died from aspiration pneumonia before
starting postsurgical adjuvant therapy. There are 17
patients still alive in follow-up, with all being followed
for at least 36 months postsurgery.
Eight SAEs were reported during treatment and
the 30-day postoperative period in 7 patients, includ-
ing 3 patients with aspiration pneumonia, 1 patient
with asthma exacerbation secondary to upper respira-
tory infection, 1 patient with a postoperative wound
infection, 1 patient with a neck abscess, and 1 patient
with an episode of alcohol withdrawal. Only 1 case of
aspiration pneumonia was deemed life threatening
(grade 4). None of the SAEs was considered related to
treatment except for the postoperative wound infec-
tion, which was considered possibly related. All AEs
resolved without sequelae. Other minor (grade 1 or 2)
AEs included headache (30%), injection-site pain
(22%), nausea (22%), constipation (15%), dizziness
(15%), fatigue (11%), and myalgia (7%). There were
minor (grade 1) alterations in posttreatment lab val-
ues. The most common (>5%) shifts from normal at
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baseline to a toxicity at day 21 were observed for
decreased hemoglobin (18.5%), decreased leukocytes
(7.4%), high non-fasting glucose (48.1%), and
decreased albumin (18.5%). At day 21, the only labora-
tory parameter that worsened more than 1 grade from
baseline was phosphate (3-grade worsening in 1
patient, 3.7%). No important mean changes in vital
sign assessments were detected at any time point
through day 21.
There were no unplanned delays in surgery as a
result of the immunotherapy regimen. Mean time from
date of informed consent to surgery was 31 days
(range, 22–47 days). Mean time from the last dose of
the regimen to surgery was 5 days (range, 1–11 days).
All patients underwent extirpative surgery as planned
before treatment, except for 1 patient who had more
extensive tumor than expected, which would have
required a total glossectomy. This patient refused sur-
gery. Surgery and wound healing were uneventful in
all patients but 1; this patient developed an early
wound infection. There were no ﬁstulae. A total of 9
patients (35%) had close margins on ﬁnal pathology,
and 1 (4%) had a microscopically positive margin. A
total of 17 patients (65%) had histologically positive
nodes, of whom 13 patients (50%) had multiple positive
nodes and 6 patients had extracapsular extension.
Overall, the pattern of SAEs with the immuno-
therapy regimen was consistent with that expected in
this patient population and did not suggest that the
regimen was associated with the occurrence of any
unique SAEs. Patients’ symptoms and signs were sub-
jectively assessed by clinical investigators at both
baseline and at day 21 after the start of immunother-
apy treatment. Clinical investigators described post-
immunotherapy regimen tumor ‘‘softening’’ in 4
patients. Decreased pain was reported by 5 patients,
and improved swallowing was reported by 4 patients.
There were no signiﬁcant progressive symptoms in ei-
ther breathing or tumor bleeding among the patients.
Tumor Response. Clinical response of the tumor after
the 21-day regimen before surgery was assessed by clini-
cal examination and radiographic imaging (CT or MRI).
All images were reviewed by an independent central
imaging group (Perceptive Informatics, Waltham, MA)
and graded using modiﬁed RECIST. A total of 25
patients had images that were satisfactory for review.
Two more patients were non-evaluable because of
imaging artifact from extensive dental restorations, or
because the tumor could not be deﬁnitely identiﬁed at
baseline. Thus, in 23 patients, the primary tumor was
evaluable, and in 16 patients, at least 1 lymph node was
evaluable for imaging response. Overall, there was mod-
est tumor shrinkage as measured by RECIST criteria at
the end of the 21-day treatment period just before sur-
gery (Figure 1). Based on target lesion (sum of longest di-
ameter), evaluation of the 23 evaluable patients, 4
patients had 20% to <10% change, 7 patients had
10% to <0% change, 9 patients had 0% to <10%
change, 1 patient had 10% to <20% change, no patients
had 20% to <30% change, and 2 patients had 30%
change in tumor (target lesion) size. Based on the overall
assessment, 19 patients (83%) had stable disease and 4
patients (17%) had some tumor growth at day 21 (com-
pletion of immunotherapy before surgery). Two of the 4
patients had some tumor growth at day 21, as measured
by the target lesions. One of the 4 patients had a
13.37% change in the target lesions, but was classiﬁed
as progressive disease because of a new small non-target
focus node; and 1 patient with a 3.66% change in the
target lesion longest diameter also had a new left side
node (non-target lesion) plus an enlarged jugulodigastric
node and was classiﬁed as having progressive disease.
There were no obvious deleterious effects in the 2
patients with tumor progression by RECIST on day
21. In the event that a tumor progressed during the
21-day regimen, the surgeon had the option of with-
drawing the patient from the immunotherapy regi-
men and proceeding directly to surgery. No surgeon
opted to withdraw a patient. One patient had surgery
earlier than planned due to clinical enlargement of
the primary tumor. For most patients, there was little
apparent change in tumor/node size. Review of the
radiologic ﬁndings in relation to the pathology nodal
status made it apparent that lymph node enlarge-
ment due to reactive hyperplasia could not be distin-
guished from that due to tumor involvement based on
a CT or MRI scan.
It is of interest that 1 patient with tongue base
cancer underwent a ﬂuorodeoxyglucose-PET CT scan
at baseline and at completion of the immunotherapy
regimen. In 2 lymph nodes and the tumor, this
patient showed elevated pretreatment glycolytic activ-
ity; the mean decrease in glycolytic activity in these
tumors was 75% after therapy (Figure 2).
FIGURE 1. Central diagnostic radiology assessment of target
lesions using modiﬁed Response Evaluation Criteria in Solid
Tumors (RECIST) at 3 weeks (percent change from baseline).
One patient was adjudged by the central reviewer to be a com-
plete response. CT/MRI of this site showed a 17.2% change
(bar with diagonal stripes), which was in concurrence with the
pathology report.
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Survival. After over more than 36 months of follow-
up, 11 of the 27 patients enrolled in this study have
experienced tumor relapse (n ¼ 1) or death (n ¼ 10).
Figures 3 and 4, show DFS and OS from the date of
surgery in the 26 patients completing surgery, respec-
tively. The pattern of ﬁrst HNSCC relapse included 3
patients with primary site recurrence, 2 with recur-
rences in the neck, and 2 with distant metastases. Of
the 10 patients who died, 6 died of cancer (1 from a
new primary) and 4 died of other causes. The 1-year,
2-year, and 3-year DFS probabilities after surgery
were 72%, 64%, and 62%, respectively. Of the 26
patients whose primary tumor was resected surgi-
cally, 2 patients died during the ﬁrst year and 5
patients died during the second year after surgery.
The probability of surviving after surgery was 92%
the ﬁrst year, 73% the second year, and 69% the third
year. Median DFS or OS were not reached after all
patients were followed for at least 3 years.
Histologic Results and Survival. Representative
posttreatment tumor samples were available from 24
patients and submitted for central independent pa-
thology review (PhenoPath Labs, Seattle, WA). Three
patients had no grading for tumor lymphocytic inﬁl-
tration because the tumor was not surgically resected,
the tumor specimen was too small, or no tumor was
evident in the tumor resection. A lymphocyte inﬁltra-
tion 100-mm VAS score was used for analysis, in
which 100 mm signiﬁed lymphocyte inﬁltration of the
entire primary tumor section and 0 mm signiﬁed no
lymphocyte inﬁltration in the tumor specimen. The
mean VAS score for all patients was 22.6 mm on the
samples obtained at surgery. Patients were grouped
into a low VAS score (below the overall mean) and
high VAS score (above the overall mean) cohort.
There were 14 patients in the low VAS score cohort
with scores between 2 and 21 (median of 9.5), and
there were 10 patients in the high VAS score cohort
FIGURE 2. Fluorodeoxyglucose-positron emission tomography (FDG-PET) CT scan at baseline and before surgery at the completion of
immunotherapy regimen (IRX-2) therapy.
FIGURE 3. Disease-free survival from date of surgery. FIGURE 4. Overall survival from date of surgery.
Neoadjuvant Immunotherapy Regimen Safety and Survival HEAD & NECK—DOI 10.1002/hed December 2011 1671
with scores between 27 and 66 (median of 37.0).
Patients in the high-LI group included fewer oral cav-
ity patients (50% in high LI vs 60% in low LI) but
were similar with respect to tumor sites. Seventy per-
cent of high-LI patients were stage IV, whereas only
60% of low LI were stage IV. The LI score was used
to determine whether the degree of LI correlated with
survival. Patients with a high-LI score had an
improved survival trend compared to those with low
LI, and superior to the survival rate for the combined
overall group (Figure 5).
DISCUSSION
This phase 2, multi-institutional, clinical trial was
conducted to determine the safety and efﬁcacy of a
regimen of neoadjuvant immune reconstitution, in
newly diagnosed patients with HNSCC who were to
undergo surgery with curative intent. The results
conﬁrm the feasibility and modest toxicity with this
low-dose, physiologic cytokine regimen. The regimen
has been shown to have a favorable safety proﬁle in
this study and in a prior phase 1 trial.18 Most AEs
were grade 1 or 2, with the predominant ones being
headache, injection-site pain, nausea, constipation,
dizziness, anemia, and fatigue. All patients completed
the immunotherapy regimen, and delays in surgery
beyond the 3-week treatment period were rare. Only
1 SAE (postoperative wound infection) was felt to be
possibly related to the immunotherapy and this event
only resulted in slight prolongation of hospitalization
after surgery. All participating investigators were
skilled head and neck surgeons with extensive clinical
experience. There was no increase in surgical compli-
cations, rate of positive surgical margins, or compro-
mise of surgical resection reported by any
investigator compared to what is usually expected in
this patient population. Although the trial was not
randomized and the treatment period was brief, it
was encouraging to see symptomatic improvement
and clinical decrease in tumor size among some indi-
vidual patients. An improvement in tumor status
over this short neoadjuvant period of 3 to 4 weeks in
this trial was not expected.
The immune regimen seemed less toxic than typi-
cally experienced with high-dose cytokine therapy or
neoadjuvant chemotherapy. Locoregional delivery of
physiologic doses of cytokines may reduce systemic
toxicity. Most recombinant cytokines, such as IL-2,
are tested in the same manner as traditional oncology
drugs, where the maximum tolerated dose is sought.
Typical cytokine therapies in cancer treatment use
extremely high doses, in the millions of units per
administration.19–22 Thus, AEs such as fever, hypo-
tension, malaise, anemia, leukopenia, and hepatic
and renal dysfunction are commonly reported, and of-
ten lead to discontinuation of the treatment.20,22 In
addition, it is theoretically possible that such high-
dose immune modulation will lead to feedback sup-
pressive effects. IV administration of cytokines is fre-
quently associated with an acute phase reaction
characterized by rigors, fever, an increase in neutro-
phils, a decrease in lymphocytes, and changes in hor-
mone levels.19 The current regimen, which contains
physiologic quantities of ILs, showed greatly
improved tolerability over typical recombinant cyto-
kine therapies. Regional administration was expected
to reduce systemic toxicity by lowering circulating
concentration in the normal tissues, and also provide
higher concentrations to the tumor-draining lymph
nodes.
In this trial, a low-dose cytokine-containing bio-
logic was delivered subcutaneously near the tumor-
draining lymph nodes where the priming of an antitu-
mor response is thought to begin. Indirect evidence
that an immunologically mediated antitumor effect
may be occurring is suggested by pronounced lympho-
cytic inﬁltration seen in some tumors and by the tu-
mor reductions observed at the end of the 21-day
regimen in 11 patients, and by a mean 75% reduction
of glycolytic activity in the tumor and lymph nodes on
posttreatment PET scan in 1 patient. Enhanced
immune response has been shown to correlate with
positive outcomes for patients with cancer. For exam-
ple, the presence of tumor-inﬁltrating T cells has been
correlated with improved progression-free survival
and/or OS in various cancers, including advanced
ovarian cancer,23 advanced melanoma,24 and
HNSCC.25 Because the immunobiology of HNSCC is
so intimately associated with the host immune sys-
tem, the reversal of immunosuppression is a particu-
larly attractive therapeutic goal for patients with this
tumor type.
In preclinical studies, the cytokine-containing bio-
logic used in this trial has been shown to be a potent
activator of dendritic cells (DCs).12 Low-dose cytokine
treatment of DCs has resulted in the upregulation of
major histocompatibility-II and intercellular adhesion
molecule-1 expression, markers associated with anti-
gen presentation. Furthermore, it caused an increase
in CD86 and CD40 protein expression, both of which
FIGURE 5. Overall survival – high lymphocytic inﬁltrate (LI) ver-
sus low LI. Immunotherapy regimen (IRX-2).
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are directly involved in T cell stimulation. It also
caused an increase in both CD83 protein expression
and the percentage of cells expressing CD83, a marker
for DC maturation. Treated DCs were able to effec-
tively stimulate and cause proliferation of allogeneic T
cells as compared to untreated DCs.
The cytokine-containing biologic was recently
shown to protect human T cells in vitro from apopto-
sis in response to several stimuli including tumor-
derived FasLþ microvesicles.26 Inhibition of apoptosis
was both dose-dependent and time-dependent and
was equivalent or better than that provided by higher
concentrations of IL-2, IL-7, and/or IL-15. These
results further bolster the argument that the multiple
cytokines act synergistically. A detailed evaluation of
the molecular pathways involved in tumor-mediated
apoptosis revealed that this biologic targets Akt via
Jak3/STAT 5 signaling and thereby restores the bal-
ance of pro-apoptotic versus anti-apoptotic proteins in
the direction of survival. Collectively, these data indi-
cate that low-dose cytokines are a potent activator of
human DCs, protects T cells from tumor-induced apo-
ptosis, and thus may be able to overcome tumor-medi-
ated suppression of cellular immunity.
IL-2 has been administered to patients with
HNSCC using a variety of delivery methods, includ-
ing intralesional injection (recombinant IL-2), syn-
thetic gene delivery systems, and primary cell-derived
cytokines with or without cyclophosphamide and in-
domethacin. Clinical responses and tumor histologic
changes have been reported that have been inter-
preted as derived from immune-rejection phenom-
ena.27 A major advantage of the current regimen is
use of physiologic quantities of IL-2 administered
with a variety of other low-dose cytokines that may
be important in restoring immune homeostasis and
modulating the overall response. A concomitant non-
cytotoxic dose of cyclophosphamide was used to
reduce the negative effects of regulatory T cells com-
bined with indomethacin-induced prostaglandin inhi-
bition to reduce immunosuppressive chronic
inﬂammation in the tumor microenvironment.
A second ﬁnding of the current study was that
some tumors showed some decrease in overall size af-
ter the immunotherapy regimen. Overall tumor
shrinkage was modest, although in 4 patients, inde-
pendent, objective imaging documented a >10%
decrease in tumor size. This was unexpected and
encouraging after only 3 weeks of presurgical neoad-
juvant immunotherapy. No patient achieved a true
partial response by RECIST criteria. Increases in tu-
mor measurements were also seen in some patients,
but most patients showed negligible change in tumor
dimensions. These ﬁndings support the safety of the
neoadjuvant regimen.
This phase 2 trial did not include a randomized
control cohort. However, the disease-free and OS
rates with reasonably long follow-up were very good.
Median DFS or OS were not reached after all patients
were followed for at least 3 years. We believe the
safety results and feasibility of this immunotherapy
regimen are intriguing enough to warrant further
study and appropriate comparison in a randomized
trial. New therapies are needed for patients with
HNSCC. Patients with advanced, surgically resecta-
ble cancers typically receive adjuvant radiation and/
or chemotherapy, but maximum toxicity has been
reached without signiﬁcant improvement in survival,
and new therapies capable of combination with cur-
rent chemotherapy/radiation treatments and with
acceptable safety proﬁles are needed.
Interestingly, LI in resected tumor specimens was
considered high in 40% of the patients. The 10
patients with a high-LI score showed an improved
survival trend in comparison to the low-LI group (n ¼
15) and to the entire study population (n ¼ 26). It is
difﬁcult to directly compare these subgroups, because
there was some imbalance, with a slightly higher per-
centage of oral cavity patients in the low-LI group.
Detailed immunologic studies of peripheral blood and
tumor inﬁltrates from tissue specimens from this clin-
ical trial are underway and will be reported sepa-
rately. In the absence of a randomized control, it is
impossible to directly attribute the LI to the immuno-
therapy regimen. In addition, further studies are
needed to determine if increases in lymphocyte subpo-
pulation inﬁltrates in the tumor are associated with
functional changes in tumor immunity or with tumor
regressions, which could lead to more speciﬁc patient
selection and further improvements in survival.
In conclusion, the results of this small, phase 2
clinical trial indicate that this neoadjuvant immuno-
therapy regimen is safe and well tolerated in
patients with newly diagnosed HNSCC who are
undergoing surgery for curative intent. The safety of
the treatment makes it feasible for a patient popula-
tion that is going to receive maximally tolerable
doses of radiation and chemotherapy. OS results are
encouraging.
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